America’s health report card reveals a troubling story. Weight-related diseases, heart conditions, and cancer take years from loved ones’ lives and place a heavy burden on the economy. The National Institutes of Health (NIH) has responded with a 2026 budget request of $27.9 billion and a clear message: scientific discovery must lead to longer, healthier lives for all Americans. Stanford physician-economist Jay Bhattacharya, M.D., Ph.D., summarizes that goal into a rallying cry—“Make America Healthy Again”—and outlines five practical guideposts that will influence how the agency allocates those funds.

1. Population Health: The First Priority: NIH investigators will evaluate every petri dish, algorithm, and clinical protocol by a single standard: Does it reduce the chronic disease burden families face daily? With over four in ten adults living with obesity and nearly one in three children facing a lifetime risk of diabetes, incremental progress is insufficient. Basic science remains vital, but the current focus must directly translate to real-world impact, whether through community trials testing food-as-medicine programs or genomic studies exploring why some neighborhoods experience higher cancer mortality rates.

2. Scientific Rigor Is Non-Negotiable: Reproducibility issues have long plagued biomedical research. Faulty methods waste money and, worse, delay cures. The agency will tighten requirements on study design, statistical power, and data sharing. Pre-registered protocols, open-access code, and cross-lab replication will become standard, not optional extras. When the public invests nearly $28 billion, trust depends on evidence that can withstand scrutiny.

3. Fresh Thinking and Shared Expertise: Great science seldom develops in isolation. Breakthroughs often happen when a chemist consults with a behavioral economist or when an engineer’s microfluidic chip intersects with an oncologist’s intuition. The NIH aims to fund cross-disciplinary teams, speed up technology transfer, and welcome start-ups, community clinics, and patient advocates. Expect artificial intelligence, gene-editing platforms, and rapid diagnostics to move from buzzwords to lab tools—and then to bedside solutions—much faster than in past funding cycles.

4. Safety and Transparency: Gain-of-function experiments, synthetic biology, and first-in-human gene therapies can save lives; however, they can also provoke fear if adequate controls are not in place. The new standard requires that every grantee evaluate potential benefits against worst-case scenarios, publish oversight plans before the first pipette touches a test tube, and report adverse events in near real-time. Open lab notebooks and public dashboards will enable taxpayers to see how their investment balances risks.

5. Freedom of Thought Drives Progress: Scientific consensus provides stability, but can also become rigid around outdated models. Dr. Bhattacharya urges the NIH to support dissenting voices that challenge dogma, whether questioning current diet guidelines, suggesting new approaches for Alzheimer’s, or rethinking viral transmission dynamics. History shows that groundbreaking ideas—such as Helicobacter causing ulcers and immunotherapy for cancer—started on the fringe.

Pursuing safe bets alone would limit the agency to small gains. The NIH Common Fund’s High-Risk, High-Reward (HRHR) program supports scientists willing to pursue high-risk questions with the potential for transformative impact. Past HRHR grants have laid the groundwork for age-reversal strategies at the cellular level, bacterial “living medicines” that reduce intestinal inflammation, and neural-circuit interventions that restore glucose regulation in diabetes. These projects share a common trait: they risk failure because success would fundamentally change textbooks. The new budget maintains that momentum. Applicants may propose initiatives ranging from quantum-enabled imaging to community-led mental health projects, as long as they can demonstrate that, if successful, their work could significantly impact how diseases are prevented or treated nationwide.

The NIH will launch two new initiatives aimed at rebuilding public trust. The first focuses on understanding Autism Spectrum Disorders (ASD). CDC estimates now show that one in thirty-one U.S. children has ASD, a number that has increased sharply over the past decade. Families face emotional and financial challenges, while clinicians continue to debate the causes and best treatments. The NIH Understanding ASD Initiative aims to combine genetic, environmental, immunological, and social data into a unified analysis framework. Researchers will utilize molecular tools in conjunction with large-scale epidemiology and collaborate with parent groups to identify priorities that matter most to families managing autism daily. The long-term goal extends beyond treatment to include preventive strategies that could alter future incidence rates. The second initiative is ORIVA, focusing on the development of human-based research models. Animal studies have advanced biomedical science for over a century, but mice do not always accurately predict human responses to drugs. Technologies such as organ-on-chip devices, stem cell-derived organoids, advanced computational models, and real-world electronic health data now provide additional—or sometimes superior—ways to test hypotheses. To promote their adoption, NIH will establish the Office of Research Innovation, Validation, and Application (ORIVA). This new office will coordinate grant opportunities, validation processes, and regulatory discussions, aiming to replace or reduce animal testing when alternative methods can yield equally or more accurate predictions. The agency is not abandoning animal research; instead, it is enhancing its toolkit to ensure each experiment uses the most appropriate model to inform human health.

Whether you work in a hospital, build health-tech start-ups, manage employer wellness benefits, or teach the next generation of clinicians, NIH policy influences your daily work. Grant priorities determine which diagnostics reach your lab bench. Reproducibility standards shape journal policies and, in turn, the evidence you cite when approaching payers. A move toward community-engaged research affects how health systems design outreach for hypertension screening. ORIVA’s efforts could shorten the journey from prototype to FDA-approved device, reducing capital needs for entrepreneurs. On a broader scale, the focus on population health aligns with the rising trend of value-based purchasing by government and private insurers. Employers spend nearly $1 trillion on health coverage, much of which is related to conditions that the NIH now considers urgent. Investing in thorough, transparent, high-impact science today leads to a healthier, more productive workforce in the future.

“Make America Healthy Again” is more than a slogan. It is a call to blend curiosity with responsibility, innovation with honesty, and discovery with tangible benefits. Suppose NIH—and everyone involved with its mission—can uphold these commitments. In that case, the next decade might bring not only new treatments but also a society where fewer families fear the chronic-disease diagnoses that seem unavoidable today.